Sphera Funds Management Ltd. Autolus Therapeutics PLC Transaction History

Sphera Funds Management Ltd.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$1.74 - $3.27 $870,000 - $1.64 Million	500,000 New	500,000 $950,000
Q3 2019 Nov 14, 2019	SELL	$9.79 - $16.72 $1.74 Million - $2.97 Million	-177,546 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$15.1 - $31.25 $233,264 - $482,750	-15,448 Reduced 8.0%	177,546 $0
Q1 2019 May 15, 2019	SELL	$24.38 - $34.71 $243,800 - $347,100	-10,000 Reduced 4.93%	192,994 $6.07 Million
Q4 2018 Feb 14, 2019	SELL	$24.21 - $48.01 $2.26 Million - $4.48 Million	-93,257 Reduced 31.48%	202,994 $6.67 Million
Q3 2018 Nov 14, 2018	BUY	$20.86 - $33.33 $2.51 Million - $4.01 Million	120,206 Added 68.28%	296,251 $8.94 Million
Q2 2018 Aug 13, 2018	BUY	$25.0 - $27.75 $4.4 Million - $4.89 Million	176,045 New	176,045 $4.72 Million

104

163M

2.8K

13.4K

Ticker AUTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,909,800
Market Cap $205M
Description
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...

Get notified when there are updates to the investment portfolio of Sphera Funds Management Ltd., based on Form 13F filings with the SEC.

Stay updated on Sphera Funds Management Ltd. with notifications on news.